Learn how IVIG works to treat and manage HDFN, as well as other treatments that may improve an HDFN-affected infant's ...

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical ...

GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Learn more about how corticosteroids given before birth can improve outcomes for infants born prematurely, including those ...

There is an undeniable connection between a strong immune system and nutrition. Learn why what you eat matters and other ways ...

At Dyadic, we remain committed to leveraging our innovative C1 and Dapibus protein production platforms to address some of the most pressing ...

Johnson & Johnson today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment ...

Passive anti-D immune globulin administered to prevent anti-D antibody formation in RhD-negative women who carry and are exposed to RhD-positive fetal RBCs; once called Rh "sensitization," this is ...

Jan. 3, 2025 — Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...